West had a record-breaking year in 2020, with sales and margins driven by base business demand and COVID-19 vaccine and therapeutic components. The company saw a 36.4% consolidated gross profit margin in Q4 2020, up from 32.5% in Q4 2019. West's capacity expansions and investments in high-value products have positioned it to meet the increased demand for COVID-19 vaccines. For 2021, the company estimates net sales to be between $2.5 billion and $2.525 billion, with an organic sales growth of 13% to 14%. Reported diluted earnings per share guidance is expected to be in the range of $6 to $6.15. West remains focused on supporting its customers in resolving the pandemic, with its products being used in the battle against COVID-19.